Mobile

Randomised controlled trial of the short term effects of OROS-methylphenidate on ADHD symptoms and behavioural outcomes in young male prisoners with attention deficit hyperactivity disorder

Mise à jour : Il y a 4 ans
Référence : EUCTR2015-004271-78

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

This is an 8-week randomised placebo controlled trial of OROS-MPH, in young adult prisoners meeting diagnostic criteria for ADHD. OROS-MPH is a long acting stimulant medication used to treat ADHD. The primary objective is to establish the efficacy of OROS-MPH in reducing ADHD symptoms (inattention and hyperactivity-impulsivity) in young male offenders aged 16-25, meeting diagnostic criteria for DSM-5 ADHD.

Critère d'inclusion

  • Attention-Deficit/Hyperactivity Disorder (ADHD)

Liens